CoChat
Sign Up
Cited by 72Lipoproteins and Cardiovascular HealthDiabetes, Cardiovascular Risks, and LipoproteinsCholesterol and Lipid Metabolism

Evidence for changing lipid management strategy to focus on non-high density lipoprotein cholesterol

Open access
Su, Xin, Kong, Yi, Peng, Daoquan·2019·Lipids in Health and Disease
DOI 10.1186/s12944-019-1080-xPMC PMC6554877
Open this paper in CoChat — free account

Abstract

Low-density lipoprotein cholesterol (LDL-C) has been recommended as the primary treatment target on lipid management in coronary heart disease (CHD) patients for past several decades. However, even by aggressive LDL-C lowering treatment, patients still present a significant residual risk of major adverse cardiovascular events (MACE). Non-high-density lipoprotein cholesterol (non-HDL-C) contained all the atherogenic lipoproteins, such as chylomicron, very-low density lipoprotein (VLDL), LDL, intermediate density lipoprotein (IDL). Many prospective observation studies have found that non-HDL-C was better than LDL-C in predicting risks of MACE. Since non-HDL-C appears to be superior for risk prediction beyond LDL-C, current guidelines have emphasize the importance of non-HDL-C for guiding cardiovascular prevention strategies and have flagged non-HDL-C as a co-primary therapeutic target. The goals of non-HDL-C were recommended as 30 mg/dl higher than the corresponding LDL-C goals, but the value seemed inappropriate. This review provide evidence for changing lipid management strategy to focus on non-HDL-C and appropriate values for adding to LDL-C goals would be proposed.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1186/s12944-019-1080-x

Cites

11 of 11 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • A decrease in atherogenic lipoproteins and sub-fractions is associated with a similar reduction in coronary heart disease.

    “Such a decrease in atherogenic lipoproteins and sub-fractions is also associated with a similar reduction in coronary heart disease [105–107].”

    From Estimating the Effect of Aerobic Exercise Training on Novel Lipid Biomarkers: A Systematic Review and Multivariate Meta-Analysis of Randomized Controlled Trials (2023) · cites this paper as [106]

    The ‘Non-HDL-C as a better target of lipid-lowering therapy’ section reports an approximately one-to-one relationship between percentage non-HDL-C lowering and CHD reduction for most lipid-modifying drugs used alone. The Introduction says non-HDL-C encompasses multiple atherogenic lipoproteins, but the reported relationship concerns their combined measure, not reductions in each lipoprotein sub-fraction separately. Page numbers are unavailable in our copy. (LLM, conf=0.82)

    Experimental — accuracy not yet measured

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Research works printed but not linked: 65

  1. [1]Zhang XH Lu ZL Liu L Coronary heart disease in China Heart 2008 94 1126 1131 10.1136/hrt.2007.132423 18703693 · DOI
  2. [2]Zhang Y Wu NQ Li S Zhu CG Guo YL Qing P Gao Y Li XL Liu G Dong Q Li JJ Non-HDL-C is a better predictor for the severity of coronary atherosclerosis compared with LDL-C Heart Lung and Circulation 2016 25 975 981 10.1016/j.hlc.2016.04.025 27634241 · DOI
  3. [3]Zhou MG Wang HD Zhu J Chen WQ Wang LH Liu SW Li YC Wang LJ Liu YN Yin P Cause-specific mortality for 240 causes in China during 1990-2013: a systematic subnational analysis for the global burden of disease study 2013 Lancet 2016 387 251 272 10.1016/S0140-6736(15)00551-6 26510778 · DOI
  4. [4]Hovingh GK Davidson MH Kastelein JJP O'Connor AM Diagnosis and treatment of familial hypercholesterolaemia Eur Heart J 2013 34 962 10.1093/eurheartj/eht015 23416791 · DOI
  5. [5]Raal FJ Hovingh GK Catapano AL Familial hypercholesterolemia treatments: guidelines and new therapies Atherosclerosis 2018 277 483 492 10.1016/j.atherosclerosis.2018.06.859 30270089 · DOI
  6. [6]Stein EA Management of dyslipidemia in the high-risk patient Am Heart J 2002 144 S43 S50 10.1067/mhj.2002.130302 12486415 · DOI
  7. [7]Feldman HA Zuber K Davis J Dyslipidemia how low should we go? A review of current lipid guidelines Physician Assistant Clinics 2017 2 633 650 10.1016/j.cpha.2017.06.004 · DOI
  8. [8]Stroes E Statins and LDL-cholesterol lowering: an overview Curr Med Res Opin 2005 21 S9 S16 10.1185/030079905X59102 16138936 · DOI
  9. [9]Dembowski E Davidson MH A review of lipid management in primary and secondary prevention J Cardiopulm Rehabil Prev 2009 29 2 12 10.1097/HCR.0b013e318192754e 19158581 · DOI
  10. [10]Shimizu R Torii H Yasuda D Hiraoka Y Kitada N Hashida T Yoshimoto A Kita T Kume N Serum lipid goal attainment in chronic kidney disease (CKD) patients under the Japan atherosclerosis society (JAS) 2012 guidelines J Atheroscler Thromb 2015 22 949 957 10.5551/jat.29165 25843151 · DOI
  11. [11]Shirai K Obesity as the core of the metabolic syndrome and the management of coronary heart disease Curr Med Res Opin 2004 20 295 304 10.1185/030079903125003008 15025838 · DOI
  12. [12]Stone NJ Robinson JG Lichtenstein AH Merz CNB Blum CB Eckel RH Goldberg AC Gordon D Levy D Lloyd-Jones DM 2013 ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults A Report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines Journal of the American College of Cardiology 2014 63 2889 2934 10.1016/j.jacc.2013.11.002 24239923 · DOI · Paper page
  13. [15]Adhyaru BB Jacobson TA New cholesterol guidelines for the Management of Atherosclerotic Cardiovascular Disease Risk a Comparison of the 2013 American College of Cardiology/American Heart Association cholesterol guidelines with the 2014 National Lipid Association Recommendations for patient-centered Management of Dyslipidemia Endocrinol Metab Clin N Am 2016 45 17 1+ 10.1016/j.ecl.2015.09.002 26892995 · DOI
  14. [16]Cziraky MJ Watson KE Talbert RL Targeting low HDL-cholesterol to decrease residual cardiovascular risk in the managed Care setting J Manag Care Pharm 2009 14 S3 S28 19891279
  15. [17]Contois JH Warnick GR Sniderman AD Reliability of low-density lipoprotein cholesterol, non-high-density lipoprotein cholesterol, and apolipoprotein B measurement J Clin Lipidol 2011 5 264 272 10.1016/j.jacl.2011.05.004 21784371 · DOI · Paper page
  16. [19]Enkhmaa B Prakash N Berglund L Non-HDL-C levels and residual cardiovascular risk: do population-specific precision approaches offer any advantages? Atherosclerosis 2018 274 230 231 10.1016/j.atherosclerosis.2018.05.010 29764695 PMC7098672 · DOI
  17. [20]Grundy SM Arai H Barter P Bersot TP Betteridge J Carmena R Cuevas A Davidson MH Genest J Kesaniemi YA An international atherosclerosis society position paper: global recommendations for the management of dyslipidemia Journal of Clinical Lipidology 2013 7 561 565 10.1016/j.jacl.2013.10.001 24314355 · DOI
  18. [22]Pedersen TR Tobert JA Simvastatin: a review Expert Opin Pharmacother 2004 5 2583 2596 10.1517/14656566.5.12.2583 15571475 · DOI
  19. [23]Lindgren P Jonsson B From 4S to IDEAL: the health economics of the statin trials Eur J Cardiovasc Prev Rehabil 2009 16 138 143 10.1097/HJR.0b013e328325d7dc 19378393 · DOI
  20. [24]Simes RJ Marschner IC Hunt D Colquhoun D Sullivan D Stewart RAH Hague W Keech A Thompson P White H Relationship between lipid levels and clinical outcomes in the long-term intervention with pravastatin in ischemic disease (LIPID) trial - to what extent is the reduction in coronary events with pravastatin explained by on-study lipid levels? Circulation 2002 105 1162 1169 10.1161/hc1002.105136 11889008 · DOI
  21. [25]Cui JS, Forbes A, Kirby A, Marschner I, Simes J, Hunt D, West M, Tonkin A. Semi-parametric risk prediction models for recurrent cardiovascular events in the LIPID study. BMC Med Res Methodol. 2010;10. PMC2856584 20356409
  22. [26]Novack V MacFadyen J Malhotra A Almog Y Glynn RJ Ridker PM The effect of rosuvastatin on incident pneumonia: results from the JUPITER trial Can Med Assoc J 2012 184 E367 E372 10.1503/cmaj.111017 22431901 PMC3328541 · DOI
  23. [29]Ip CK Jin DM Gao JJ Meng Z Meng J Tan Z Wang JF Geng DF Effects of add-on lipid-modifying therapy on top of background statin treatment on major cardiovascular events: a meta-analysis of randomized controlled trials Int J Cardiol 2015 191 138 148 10.1016/j.ijcard.2015.04.228 25965621 · DOI · Paper page
  24. [30]Ho LT Lin FJ Tseng WK Yin WH Wu YW Li YH Yeh HI Chen JW Wu CC Pat TSP On-treatment lipid profiles to predict the cardiovascular outcomes in ASCVD patients comorbid with chronic kidney disease - the multi-center T-SPARCLE registry study J Formos Med Assoc 2018 117 814 824 10.1016/j.jfma.2018.05.020 29945742 · DOI
  25. [31]Folse HJ Goswami D Rengarajan B Budoff M Kahn R Clinical- and cost-effectiveness of LDL particle-guided statin therapy: a simulation study Atherosclerosis 2014 236 154 161 10.1016/j.atherosclerosis.2014.06.027 25050538 · DOI
  26. [33]Pradhan AD Aday AW Rose LM Ridker PM Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy Circulation 2018 138 141 149 10.1161/CIRCULATIONAHA.118.034645 29716940 PMC8108606 · DOI · Paper page
  27. [34]Soran H Dent R Durrington P Evidence-based goals in LDL-C reduction Clin Res Cardiol 2017 106 237 248 10.1007/s00392-016-1069-7 28124099 PMC5360845 · DOI · Paper page
  28. [35]Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian Simvastatin Survival Study (4S). Lancet. 1994;344:1383–9. 7968073
  29. [36]Pedersen TR Kjekshus J Berg K Haghfelt T Faergeman O Faergeman G Pyorala K Miettinen T Wilhelmsen L Olsson AG Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: the Scandinavian simvastatin survival study (4S) Atheroscler Suppl 1994 5 81 87 10.1016/j.atherosclerosissup.2004.08.027 15531279 · DOI
  30. [37]Iakoubova OA Tong CH Rowland CM Kirchgessner TG Young BA Arellano AR Shiffman D Sabatine MS Campos H Packard CJ Association of the Trp719Arg polymorphism in kinesin-like protein 6 with myocardial infarction and coronary heart disease in 2 prospective trials: the CARE and WOSCOPS trials J Am Coll Cardiol 2008 51 435 443 10.1016/j.jacc.2007.05.057 18222353 · DOI
  31. [38]Lee S Cannon CP Combination lipid-lowering therapies for the prevention of recurrent cardiovascular events Curr Cardiol Rep 2018 20 55 10.1007/s11886-018-0997-4 29802475 · DOI
  32. [39]Ballantyne CM Current and future aims of lipid-lowering therapy: changing paradigms and lessons from the heart protection study on standards of efficacy and safety Am J Cardiol 2003 92 3K 9K 10.1016/S0002-9149(03)00768-9 12948870 · DOI
  33. [40]Farmer JA Gotto AM Jr The heart protection study: expanding the boundaries for high-risk coronary disease prevention Am J Cardiol 2003 92 3i 9i 10.1016/S0002-9149(03)00503-4 12867249 · DOI
  34. [41]Parish S Offer A Clarke R Hopewell JC Hill MR Otvos JD Armitage J Collins R Heart protection study collaborative G: lipids and lipoproteins and risk of different vascular events in the MRC/BHF heart protection study Circulation 2012 125 2469 2478 10.1161/CIRCULATIONAHA.111.073684 22539783 · DOI
  35. [42]Baigent C Keech A Kearney PM Blackwell L Buck G Pollicino C Kirby A Sourjina T Peto R Collins R Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins Lancet 2005 366 1267 1278 10.1016/S0140-6736(05)67394-1 16214597 · DOI · Paper page
  36. [43]Miller M Cannon CP Murphy SA Qin J Ray KK Braunwald E Investigators PI-T Impact of triglyceride levels beyond low-density lipoprotein cholesterol after acute coronary syndrome in the PROVE IT-TIMI 22 trial J Am Coll Cardiol 2008 51 724 730 10.1016/j.jacc.2007.10.038 18279736 · DOI · Paper page
  37. [44]Steen DL Umez-Eronini AA Guo J Khan N Cannon CP The effect of fasting status on lipids, lipoproteins, and inflammatory biomarkers assessed after hospitalization for an acute coronary syndrome: insights from PROVE IT-TIMI 22 Clin Cardiol 2018 41 68 73 10.1002/clc.22851 29283450 PMC6489711 · DOI
  38. [45]Wilson SR Sabatine MS Wiviott SD Ray KK De Lemos JA Zhou S Rifai N Cannon CP Morrow DA Group TS Assessment of adiponectin and the risk of recurrent cardiovascular events in patients presenting with an acute coronary syndrome: observations from the pravastatin or atorVastatin evaluation and infection trial-thrombolysis in myocardial infarction 22 (PROVE IT-TIMI 22) Am Heart J 2011 161 1147 1155 e1141 10.1016/j.ahj.2011.02.014 21641362 · DOI
  39. [47]Jarcho JA Keaney JF Jr Proof that lower is better--LDL cholesterol and IMPROVE-IT N Engl J Med 2015 372 2448 2450 10.1056/NEJMe1507041 26039520 · DOI
  40. [48]Kato ET, Cannon CP, Blazing MA, Bohula E, Guneri S, White JA, Murphy SA, Park JG, Braunwald E, Giugliano RP. Efficacy and safety of adding ezetimibe to statin therapy among women and men: insight from IMPROVE-IT (Improved reduction of outcomes: Vytorin efficacy international trial). J Am Heart Assoc. 2017;6. PMC5721774 29151034
  41. [49]Nichols GA, Philip S, Reynolds K, Granowitz CB, Fazio S. Increased residual cardiovascular risk in patients with diabetes and high versus normal triglycerides despite statin-controlled LDL cholesterol. Diabetes Obes Metab. 2018. PMC6587847 30225881
  42. [50]Cui Y Blumenthal RS Flaws JA Whiteman MK Langenberg P Bachorik PS Bush TL Non-high-density lipoprotein cholesterol level as a predictor of cardiovascular disease mortality Arch Intern Med 2001 161 1413 1419 10.1001/archinte.161.11.1413 11386890 · DOI
  43. [51]Pischon T Girman CJ Sacks FM Rifai N Stampfer MJ Rimm EB Non-high-density lipoprotein cholesterol and apolipoprotein B in the prediction of coronary heart disease in men Circulation 2005 112 3375 3383 10.1161/CIRCULATIONAHA.104.532499 16316964 · DOI · Paper page
  44. [52]Mora Samia Ridker Paul M. Justification for the Use of Statins in Primary Prevention: An Intervention Trial Evaluating Rosuvastatin (JUPITER)—Can C-Reactive Protein Be Used to Target Statin Therapy in Primary Prevention? The American Journal of Cardiology 2006 97 2 33 41 10.1016/j.amjcard.2005.11.014 16442935 · DOI
  45. [54]Sondermeijer BM Rana JS Arsenault BJ Shah PK Kastelein JJ Wareham NJ Boekholdt SM Khaw KT Non-HDL cholesterol vs. apo B for risk of coronary heart disease in healthy individuals: the EPIC-Norfolk prospective population study Eur J Clin Investig 2013 43 1009 1015 10.1111/eci.12129 23859101 · DOI · Paper page
  46. [55]Wongcharoen W Sutthiwutthichai S Gunaparn S Phrommintikul A Is non-HDL-cholesterol a better predictor of long-term outcome in patients after acute myocardial infarction compared to LDL-cholesterol?: A retrospective study BMC Cardiovasc Disord 2017 17 10 10.1186/s12872-016-0450-9 28056802 PMC5217612 · DOI
  47. [56]de Oliveira Alvim R Mourao-Junior CA Magalhaes GL de Oliveira CM Krieger JE Mill JG Pereira AC Non-HDL cholesterol is a good predictor of the risk of increased arterial stiffness in postmenopausal women in an urban Brazilian population Clinics (Sao Paulo) 2017 72 106 110 10.6061/clinics/2017(02)07 28273234 PMC5304361 · DOI
  48. [57]Rana JS Liu JY Moffet HH Boklage SH Khan I Karter AJ Risk of incident atherosclerotic cardiovascular DiseaseEvents by achieved Atherogenic lipid levels Among62,428 statin-treated individuals with diabetes mellitus Am J Cardiol 2018 122 762 767 10.1016/j.amjcard.2018.05.011 30057224 · DOI
  49. [58]Cao Y Yan L Guo N Yu N Wang Y Cao X Yang S Lv F Non-high-density lipoprotein cholesterol and risk of cardiovascular disease in the general population and patients with type 2 diabetes: a systematic review and meta-analysis Diabetes Res Clin Pract 2018 147 1 8 10.1016/j.diabres.2018.11.002 30448450 · DOI
  50. [61]Lee EY Yang Y Kim HS Cho JH Yoon KH Chung WS Lee SH Chang K Effect of visit-to-visit LDL-, HDL-, and non-HDL-cholesterol variability on mortality and cardiovascular outcomes after percutaneous coronary intervention Atherosclerosis 2018 279 1 9 10.1016/j.atherosclerosis.2018.10.012 30359786 · DOI
  51. [62]Khaloo P Hasheminia M Tohidi M Abdi H Mansournia MA Azizi F Hadaegh F Impact of 3-year changes in lipid parameters and their ratios on incident type 2 diabetes: Tehran lipid and glucose study Nutr Metab (Lond) 2018 15 50 10.1186/s12986-018-0287-6 30008790 PMC6042239 · DOI
  52. [63]Blaha MJ Blumenthal RS Brinton EA Jacobson TA Non-HDL NLAT: The importance of non-HDL cholesterol reporting in lipid management Journal of Clinical Lipidology 2008 2 267 273 10.1016/j.jacl.2008.06.013 21291742 · DOI
  53. [64]Degoma EM Davis MD Dunbar RL Mohler ER 3rd Greenland P French B Discordance between non-HDL-cholesterol and LDL-particle measurements: results from the multi-ethnic study of atherosclerosis Atherosclerosis 2013 229 517 523 10.1016/j.atherosclerosis.2013.03.012 23591415 PMC4066302 · DOI
  54. [65]Elshazly MB Quispe R Michos ED Sniderman AD Toth PP Banach M Kulkarni KR Coresh J Blumenthal RS Jones SR Martin SS Patient-level discordance in population percentiles of the Total cholesterol to high-density lipoprotein cholesterol ratio in comparison with low-density lipoprotein cholesterol and non-high-density lipoprotein cholesterol: the very large database of lipids study (VLDL-2B) Circulation 2015 132 667 676 10.1161/CIRCULATIONAHA.115.016163 26137953 PMC4550508 · DOI
  55. [66]Anderson TJ Gregoire J Hegele RA Couture P Mancini GB McPherson R Francis GA Poirier P Lau DC Grover S 2012 update of the Canadian cardiovascular society guidelines for the diagnosis and treatment of dyslipidemia for the prevention of cardiovascular disease in the adult Can J Cardiol 2013 29 151 167 10.1016/j.cjca.2012.11.032 23351925 · DOI
  56. [68]Genest J McPherson R Frohlich J Anderson T Campbell N Carpentier A Couture P Dufour R Fodor G Francis GA 2009 Canadian cardiovascular society/Canadian guidelines for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease in the adult - 2009 recommendations Can J Cardiol 2009 25 567 579 10.1016/S0828-282X(09)70715-9 19812802 PMC2782500 · DOI
  57. [69]Authors/Task Force M, Catapano AL, Graham I, De Backer G, Wiklund O, Chapman MJ, Drexel H, Hoes AW, Jennings CS, Landmesser U, et al. 2016 ESC/EAS guidelines for the Management of Dyslipidaemias: the task Force for the Management of Dyslipidaemias of the European Society of Cardiology (ESC) and European atherosclerosis society (EAS) developed with the special contribution of the European Assocciation for Cardiovascular Prevention & Rehabilitation (EACPR). Atherosclerosis. 2016(253):281–344. 27594540
  58. [70]Quispe R Manalac RJ Faridi KF Blaha MJ Toth PP Kulkarni KR Nasir K Virani SS Banach M Blumenthal RS Relationship of the triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio to the remainder of the lipid profile: the very large database of Lipids-4 (VLDL-4) study Atherosclerosis 2015 242 243 250 10.1016/j.atherosclerosis.2015.06.057 26232164 · DOI
  59. [71]Al-Hashmi K Al-Zakwani I Al Mahmeed W Arafah M Al-Hinai AT Shehab A Al Tamimi O Al Awadhi M Al Herz S Al Anazi F Non-high-density lipoprotein cholesterol target achievement in patients on lipid-lowering drugs and stratified by triglyceride levels in the Arabian gulf J Clin Lipidol 2016 10 368 377 10.1016/j.jacl.2015.12.021 27055968 · DOI
  60. [72]Pongsuthana S Tivatunsakul N Optimal fasting time before measurement of serum triglyceride levels in healthy volunteers J Med Assoc Thail 2016 99 Suppl 2 S42 S46 27266215
  61. [73]Yue F Zhang G Tang R Zhang Z Teng L Zhang Z Age- and sex-related changes in fasting plasma glucose and lipoprotein in cynomolgus monkeys Lipids Health Dis 2016 15 111 10.1186/s12944-016-0280-x 27342143 PMC4919873 · DOI
  62. [74]Ballantyne CM Pitt B Loscalzo J Cain VA Raichlen JS Alteration of relation of atherogenic lipoprotein cholesterol to apolipoprotein B by intensive statin therapy in patients with acute coronary syndrome (from the limiting UNdertreatment of lipids in ACS with Rosuvastatin [LUNAR] trial) Am J Cardiol 2013 111 506 509 10.1016/j.amjcard.2012.10.037 23237107 · DOI
  63. [75]Elshazly MB Martin SS Blaha MJ Joshi PH Toth PP McEvoy JW Al-Hijji MA Kulkarni KR Kwiterovich PO Blumenthal RS Jones SR Non-high-density lipoprotein cholesterol, guideline targets, and population percentiles for secondary prevention in 1.3 million adults: the VLDL-2 study (very large database of lipids) J Am Coll Cardiol 2013 62 1960 1965 10.1016/j.jacc.2013.07.045 23973689 · DOI · Paper page
  64. [76]Kuwabara K Harada S Sugiyama D Kurihara A Kubota Y Higashiyama A Hirata T Nishida Y Kawasaki M Takebayashi T Okamura T Relationship between non-high-density lipoprotein cholesterol and low-density lipoprotein cholesterol in the general population J Atheroscler Thromb 2016 23 477 490 10.5551/jat.33100 26961218 · DOI · Paper page
  65. [77]Brito FA Pedrosa W Maluf CB dos Reis RCP Fedeli LMG Castilhos C Barreto SM Vidigal PG Non-HDL-C goals based on the distribution of population percentiles in ELSA-Brasil: is it time to change? Atherosclerosis 2018 274 243 250 10.1016/j.atherosclerosis.2018.04.007 29729963 · DOI

Cited by

Sorted by citations

Authors
Su, X., Kong, Y., & Peng, D.
Affiliations
  • Second Xiangya Hospital of Central South University (CN)
  • Central South University (CN)
Corresponding author
Peng, Daoquan
ORCID
Venue
Lipids in Health and Disease
Publisher
Springer Science and Business Media LLC
Published
2019-06-07
Volume
18
Issue
1
Pages
134-134
ISSN
1476-511X (ISSN-L)
DOI
10.1186/s12944-019-1080-x
PMC
PMC6554877
OpenAlex
W2948745207
Cited by
72
References
11
Citations by year
2026: 3 · 2025: 8 · 2024: 10 · 2023: 10 · 2022: 14 · 2021: 13 · 2020: 12 · 2019: 2
FWCI
2.11
Type
journal article
Language
en
Open access
Licence
Locations
  • Lipids in Health and Disease (publishedVersion, cc-by)
  • PubMed Central (publishedVersion, cc-by)
  • PubMed (publishedVersion)
  • DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Funders
National Natural Science Foundation of China (81670426, 81870336)
Topics
  • Health Sciences › Medicine › Surgery › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes, Cardiovascular Risks, and Lipoproteins
  • Health Sciences › Medicine › Surgery › Cholesterol and Lipid Metabolism
Keywords
non-HDL cholesterol, LDL cholesterol, lipid control, coronary artery disease, major adverse cardiovascular events, residual cardiovascular risk, atherogenic lipoproteins, cardiovascular risk prediction
MeSH terms
Cardiovascular Diseases, Chylomicrons, Coronary Disease, Humans, Lipids, Cholesterol, HDL, Cholesterol, LDL, Risk Factors, Hydroxymethylglutaryl-CoA Reductase Inhibitors, Lipid Metabolism, Drug-Related Side Effects and Adverse Reactions

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review